• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.

作者信息

Hocher Berthold, Tsuprykov Oleg

机构信息

Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha 410013, China.

Institute of Nutritional Science, University of Potsdam, 14558 Nuthetal-Potsdam, Germany.

出版信息

Nat Rev Nephrol. 2017 Dec;13(12):728-730. doi: 10.1038/nrneph.2017.140. Epub 2017 Oct 9.

DOI:10.1038/nrneph.2017.140
PMID:28989173
Abstract
摘要

相似文献

1
Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.糖尿病肾病：胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂的肾脏保护作用
Nat Rev Nephrol. 2017 Dec;13(12):728-730. doi: 10.1038/nrneph.2017.140. Epub 2017 Oct 9.
2
Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.2017年的糖尿病肾病：糖尿病肾病治疗的新时代。
Nat Rev Nephrol. 2018 Feb;14(2):78-80. doi: 10.1038/nrneph.2017.182. Epub 2018 Jan 8.
3
Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.根据心肾风险选择胰高血糖素样肽-1受体激动剂或钠-葡萄糖协同转运蛋白2抑制剂。
Lancet Diabetes Endocrinol. 2020 Feb;8(2):97-99. doi: 10.1016/S2213-8587(19)30414-0. Epub 2019 Dec 13.
4
New Glucose-Lowering Agents for Diabetic Kidney Disease.新型降糖药物治疗糖尿病肾脏疾病。
Adv Chronic Kidney Dis. 2018 Mar;25(2):149-157. doi: 10.1053/j.ackd.2018.01.002.
5
Glucose lowering and the kidney: are all drug classes equal?降糖与肾脏：所有药物类别都一样吗？
Lancet Diabetes Endocrinol. 2018 Nov;6(11):835-837. doi: 10.1016/S2213-8587(18)30291-2. Epub 2018 Oct 3.
6
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管益处。
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-28.
7
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.SGLT2 抑制剂和 GLP-1 受体激动剂的肾脏获益：支持 2 型糖尿病医学管理模式转变的证据。
Int J Mol Sci. 2019 Nov 20;20(23):5831. doi: 10.3390/ijms20235831.
8
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.2 型糖尿病与肾脏：心血管结局试验的新视角。
Diabetes Obes Metab. 2019 Aug;21(8):1790-1800. doi: 10.1111/dom.13743. Epub 2019 May 2.
9
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？
Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.
10
Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.胰高血糖素样肽-1 受体激动剂对 2 型糖尿病患者肾功能及安全性的影响。
J Diabetes Investig. 2021 Jun;12(6):914-916. doi: 10.1111/jdi.13552. Epub 2021 May 7.

引用本文的文献

1
GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition.胰高血糖素样肽-1受体激动剂通过β-klotho介导的铁死亡抑制减轻糖尿病肾损伤。
Adv Sci (Weinh). 2025 Jan;12(4):e2409781. doi: 10.1002/advs.202409781. Epub 2024 Dec 4.
2
Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.比较恩格列净和利拉鲁肽对糖尿病小鼠脂代谢和肠道菌群的影响。
PeerJ. 2024 Mar 15;12:e17055. doi: 10.7717/peerj.17055. eCollection 2024.
3
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.

本文引用的文献

1
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.GLP-1 与肾脏：从生理学到药理学以及在糖尿病中的结局。
Nat Rev Nephrol. 2017 Oct;13(10):605-628. doi: 10.1038/nrneph.2017.123. Epub 2017 Sep 4.
2
Liraglutide and Renal Outcomes in Type 2 Diabetes.利拉鲁肽与 2 型糖尿病患者的肾脏结局。
N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.
3
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.恩格列净与心血管高风险2型糖尿病患者的脑血管事件
糖尿病肾病治疗策略的新进展。
Int J Mol Sci. 2022 Sep 17;23(18):10882. doi: 10.3390/ijms231810882.
4
Even high normal blood pressure affects live birth rate in women undergoing fresh embryo transfer.即使血压处于正常高值，也会影响行新鲜胚胎移植的女性的活产率。
Hum Reprod. 2022 Oct 31;37(11):2578-2588. doi: 10.1093/humrep/deac201.
5
Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals.糖尿病患者和非糖尿病患者肾功能的差异和共同遗传效应。
Commun Biol. 2022 Jun 13;5(1):580. doi: 10.1038/s42003-022-03448-z.
6
MicroRNA-10a/b inhibit TGF-β/Smad-induced renal fibrosis by targeting TGF-β receptor 1 in diabetic kidney disease.微小RNA-10a/b通过靶向糖尿病肾病中的转化生长因子-β受体1来抑制转化生长因子-β/ Smad诱导的肾纤维化。
Mol Ther Nucleic Acids. 2022 Apr 7;28:488-499. doi: 10.1016/j.omtn.2022.04.002. eCollection 2022 Jun 14.
7
The cell membrane repair protein MG53 modulates transcription factor NF-κB signaling to control kidney fibrosis.细胞膜修复蛋白 MG53 通过调节转录因子 NF-κB 信号通路来控制肾脏纤维化。
Kidney Int. 2022 Jan;101(1):119-130. doi: 10.1016/j.kint.2021.09.027. Epub 2021 Oct 30.
8
Roles of Gut Microbial Metabolites in Diabetic Kidney Disease.肠道微生物代谢物在糖尿病肾病中的作用。
Front Endocrinol (Lausanne). 2021 May 20;12:636175. doi: 10.3389/fendo.2021.636175. eCollection 2021.
9
Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity.卡格列净可减少顺铂摄取并激活 Akt 以防止顺铂诱导的肾毒性。
Am J Physiol Renal Physiol. 2020 Apr 1;318(4):F1041-F1052. doi: 10.1152/ajprenal.00512.2019. Epub 2020 Mar 9.
10
Impact of sex on diabetic nephropathy and the renal transcriptome in UNx db/db C57BLKS mice.性别对单侧肾切除的db/db C57BLKS小鼠糖尿病肾病及肾脏转录组的影响。
Physiol Rep. 2019 Dec;7(24):e14333. doi: 10.14814/phy2.14333.
Stroke. 2017 May;48(5):1218-1225. doi: 10.1161/STROKEAHA.116.015756. Epub 2017 Apr 6.
4
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.SGLT2 抑制的肾脏、代谢和心血管考虑因素。
Nat Rev Nephrol. 2017 Jan;13(1):11-26. doi: 10.1038/nrneph.2016.170. Epub 2016 Dec 12.
5
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
6
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
7
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.二肽基肽酶抑制剂利拉利汀和血管紧张素 II 受体阻断剂替米沙坦通过不同途径在 5/6 肾切除大鼠中显示出肾脏益处。
Kidney Int. 2016 May;89(5):1049-1061. doi: 10.1016/j.kint.2016.01.016. Epub 2016 Mar 24.
8
Adenosine A1 receptor antagonists in clinical research and development.腺苷 A1 受体拮抗剂的临床研究与开发。
Kidney Int. 2010 Sep;78(5):438-45. doi: 10.1038/ki.2010.204. Epub 2010 Jun 30.
9
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.氯沙坦对2型糖尿病肾病患者肾脏和心血管结局的影响。
N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161.
10
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.血管紧张素受体拮抗剂厄贝沙坦对2型糖尿病肾病患者的肾脏保护作用。
N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303.